JavaScript is disabled for your browser. Some features of this site may not work without it.
Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy
Li, F.; Szabó, C.; Pacher, P.; Southan, G. J.; Abatan, O. I.; Charniauskaya, T.; Stevens, Martin J.; Obrosova, I. G.
Li, F.; Szabó, C.; Pacher, P.; Southan, G. J.; Abatan, O. I.; Charniauskaya, T.; Stevens, Martin J.; Obrosova, I. G.
2004-04
Citation:Li, F.; Szabó, C.; Pacher, P.; Southan, G. J.; Abatan, O. I.; Charniauskaya, T.; Stevens, M. J.; Obrosova, I. G.; (2004). "Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy." Diabetologia 47(4): 710-717. <http://hdl.handle.net/2027.42/46035>
Abstract: Poly(ADP-ribose) polymerase activation depletes NAD + and high-energy phosphates, activates protein kinase C, and affects gene expression in various tissues. This study was designed to characterise the effects of the potent, orally active poly(ADP-ribose) polymerase inhibitor PJ34 in the Wistar rat model of early diabetic neuropathy.
